60 results about "Organ protection" patented technology

Provided herein is a method of postconditioning reperfusion of an organ or tissue injured by ischemia in combination with the administration of one or more tissue protective agents that enhance the effect of postconditioning. Also provided is a method of treating a myocardial infarction in a subject to prevent injury to the heart following reperfusion of the heart in combination with the administration of one or more tissue protective agents that enhance the effect of postconditioning.

A system for perfusing a localized site within a body includes a catheter assembly having a venous access line that is adapted to deliver perfusate to the localized site, a venous or arterial drainage line adapted to drain perfusate from the localized site, and an occlusion device adapted to prevent some or substantially all physiological blood flow between the localized site and the systemic circulation of the body during and in the course of perfusing and draining perfusate to and from the localized site. The system may include a blood circuit associated with the catheter assembly to facilitate blood conditioning for use as the perfusate, in the course of a controlled perfusion and / or drainage of untreated, treated, or inactivated treated blood to and from the localized site. A delivery machine may control the blood circuit and catheter assembly in order to both deliver perfusate to, and drain some or all perfusate from, the localized site in a manner that provides perfusate to substantially only the localized site.

The device claimed refers to means for human respiration organ protection against dust-like particles - in particular, against allergen-carrying particles. It may be used as a nasal filter, as a filter in respirators, and so forth. The device comprises a hollow body having one or several inlet channels and one outlet orifice that are intended for the passage of inhaled air, with the inner surface of said body having such a shape that is close to the shape of a truncated cone, and said inlet channels are made in the major base of the cone with the direction of the axis of each of the channels being combined out of the tangential component and axial component, while the outlet orifice is made in the vertex (minor base) of the cone, and the inner body surface is covered with a sticky substance capable of retaining dust and allergen particles contained in the inhaled air.

The invention discloses a broad spectrum type tumor thermal therapy device belonging to the technical field of medical devices. The broad spectrum type tumor thermal therapy device comprises an operation platform, a whole body heating module, a local heating module, a power supply module, a heat physiological parameter monitoring system, an important organ protection module and a computer control platform, wherein the whole body heating module is used for providing a heating source used in whole body heating; the local heating module is used for providing a heating source used in local heating; the power supply module is used for providing a power supply for the whole body heating module, the local heating module, the heat physiological parameter monitoring system, the important organ protection module and the computer control platform; the heat physiological parameter monitoring system is used for measuring the temperature; the important organ protection module is used for cooling the whole body; and the computer control platform is used for electromechanically controlling other modules in the broad spectrum type tumor thermal therapy device. The broad spectrum type tumor thermal therapy device can be flexibly suitable for various therapy conditions, integrates the technical advantages of various target systems and heating sources, is improved in therapy effect, is wide in application range, and is convenient to operate.

This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and / or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ.

A system for perfusing a localized site within a body includes a catheter assembly having a venous access line that is adapted to deliver perfusate to the localized site, a venous or arterial drainage line adapted to drain perfusate from the localized site, and an occlusion device adapted to prevent some or substantially all physiological blood flow between the localized site and the systemic circulation of the body during and in the course of perfusing and draining perfusate to and from the localized site. The system may include a blood circuit associated with the catheter assembly to facilitate blood conditioning for use as the perfusate, in the course of a controlled perfusion and / or drainage of untreated, treated, or inactivated treated blood to and from the localized site. A delivery machine may control the blood circuit and catheter assembly in order to both deliver perfusate to, and drain some or all perfusate from, the localized site in a manner that provides perfusate to substantially only the localized site.

The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.

The invention relates to a medicinal composition prepared from indapamide, folic acid and a medicinally available carrier, and application of the composition for preparing a drug for treating hypertension with hyperhomocysteinemia and a disease of homocysteine rising. In the composition, the preferable content of indapamide is 0.625-2.5 mg, and the preferable content of folic acid is 0.4-0.8 mg. The medicinal composition disclosed by the invention has the benefits that indapamide and folic acid can be combined to reduce blood pressure, obviously lower level of homocysteine and raise the level of folic acid, so as to relieve damage of homocysteine to the blood vessel, strengthen targeted organ protection for a hypertension patient, and play a pharmacologic synergistic role. In addition, the medicinal composition can further allow the patient to take medicine conveniently and reduce the medical costs.

The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example

An organ protectant solution which is intravenously administerable includes a high concentration of cell impermeant molecules which have a charge and / or molecular weight which permit passage across a capillary endothelium and into an interstitial space in said subject but which are too large and / or charged to cross a cell plasma membrane such that said one or more cell impermeant molecules preferentially load into an extracellular fluid compartment can be used to to allow for improved organ harvesting from DCD and brain death donors for transplantation purposes and also can be used extend the “Golden Hour” for traumatic and hemorrhagic shock patients thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.

Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.

The invention relates to an antihypertensive medical composite which is composed of 0.5-100mg of angiotensin converting enzyme inhibitor with curative dose, 4-800mg of AT1 receptor antagonist, 0.1-50mg of one or more of B-complex vitamins and pharmaceutically acceptable carrier in one tablet. The invention has the advantages that the medical composite can increase the curative effect of the antihypertensive medicine, improve the target organ protection function of the medicine and reduce the incidence rate of complications such as fundus hemorrhage, angina pectoris, myocardial infarction, brain stroke, heart failure and kidney failure. In addition, the antihypertensive medical composite can be used to ensure the patient to take the medicine conveniently and reduce medical expenses.

The invention discloses leukocyte-depleted warm blood cardioplegic solution perfusion device, which is mainly used for the perfusion of a cardioplegic solution to the heart during open heart surgery under cardiopulmonary bypass and is also used for the perfusion of a tissue and organ protection solution. A perfusion bag is made from four layers of thin films, wherein by virtue of the four layers of the thin films, the perfusion bag is divided into a temperature regulating cavity, a medicine liquid cavity and a pressurizing cavity from left to right; a temperature regulating liquid injection tube for injecting temperature regulating liquid is arranged on the upper part of the temperature regulating cavity, and a temperature regulating liquid drainage tube for draining the temperature regulating liquid is arranged on the lower part of the temperature regulating cavity; a medicine liquid injection tube which is communicated with the medicine liquid cavity is arranged on the upper part of the medicine liquid cavity; a pressurizing and inflating tube which is communicated with the pressurizing cavity is arranged on the lower part of the pressurizing cavity; and a perfusion tube which is communicated with the medicine liquid cavity is arranged on the lower part of the medicine liquid cavity. The cardioplegic solution perfusion device disclosed by the invention has the beneficial effects that the heat of the cardioplegic solution can be preserved or increased at any time; and when the cardioplegic solution is inflated and pressurized, the perfusion device can be used for preventing air from entering the cardioplegic solution and for removing residual liquid in the perfusion bag to the greatest extent.

The invention discloses an ice-temperature organ protection solution. A sterilizing aqueous solution is prepared from potassium citrate, sodium citrate, magnesium sulfate, mannitol, 6-aminoadenine phosphate, astragalus membranaceus and water for injection by mixing. Every 100ml of the ice-temperature organ protection solution comprises 0.87-1.16g of potassium citrate, 0.98-1.19g of sodium citrate, 1.02-1.15g of magnesium sulfate, 5.56-6.85g of mannitol and 0.45g of 6-aminoadenine phosphate and 5ml of astragalus membranaceus extract. The ice-temperature organ protection solution is prepared by mixing the potassium citrate, the sodium citrate, the magnesium sulfate, the mannitol, the 6-aminoadenine phosphate and the astragalus membranaceus, and adding the water for injection into a 100ml bottle to dilute the volume to 100ml. Because the proportion of the mannitol is increased, the phase-transition temperature point of the ice-temperature organ protection solution can be decreased, and the ice-temperature organ protection solution is more suitable for preserving an organ at ice temperature. The added astragalus membranaceus has the functions of resisting the oxidative damage and promoting the activity of a Na<+>-K<+>-ATP enzyme. The ice-temperature organ protection solution has low viscosity and a good perfusion effect and can decrease the temperature of an organ rapidly in a short time.

The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

The invention discloses a heat isolation organ protection cover for a 3D printer. The problem about heat isolation protection between a current 3D printer high-temperature cavity and a motion component is solved. A plurality of waveform heat isolation layers are included. Each heat isolation layer is connected with the adjacent heat isolation layer at the position of the wave crest or the trough.After the organ protection cover is stretched, a hollow structure is formed between every two adjacent heat isolation layers. Through the hollow structures between the heat isolation layers and isolation of the multiple heat isolation layers, the heat conductivity between an upper face and a lower face of the organ protection cover is greatly reduced, good heat isolation and heat preservation performance of the heat isolation organ protection cover is achieved, and accordingly the problem about heat isolation protection between the 3D printer high-temperature cavity and the motion component issolved.

A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent in an amount effective to provide anesthesia, at normobaric conditions.

The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.

The present invention discloses a new polypeptide having a tissue protective activity. The present invention discloses a sequence, a structure and a preparation method of the polypeptide. The polypeptide has a good tissue and organ protection effect, especially provides good cure effects for inflammations of a plurality of tissues, and has characteristics of no toxicity, safety, and wide medicinal and medical application prospects.

The invention discloses a juvenile penaeus vannamei temporary rearing special feed formula and a use method thereof. The formula comprises the following main components of viable bacteria, organic acid, enzyme, trace metabolites, immunoenhancement substances, organ protection substances, energy supply substances and vitamins. A specific preparation process comprises the following steps of S1, performing superfine grinding, specifically putting 100 parts of organic acid, enzyme, trace metabolites, immunoenhancement substances, organ protection substances, energy supply substances and a vitamin mixture A into a ball mill, and performing superfine grinding to obtain a mixture B; According to the juvenile penaeus vannamei temporary rearing special feed formula and the use method thereof, through the treatment of activity retention technologies such as superfine grinding, high-temperature inactivation, aerobic and anaerobic multi-time alternate fermentation, deep kneading slow mixing, low-temperature granulation and positive-pressure anaerobic packaging, the characteristics that granular feed is low in scatter ratio in water, comprehensive in single granule nutrition, capable of conforming to the feeding habit of prawns, convenient in feeding, and the like are achieved, and the functional substance richness and the application effectiveness of a product are guaranteed.

An organ protectant solution which is intravenously administered includes a high concentration of cell-impermeant molecules and at least one oncotic agent. The cell-impermeant molecules preferentially load into the interstitial space and the oncotic agent(s) is / are restricted to the vasculature space. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, and maintaining blood circulation and oxygenation of tissues. The organ protectant solution extends the “Golden Hour” for traumatic and / or hemorrhagic shock patients, thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.

The invention discloses a crown block type graphite machining tool. The tool comprises a body, a first automatic door, a dust exhaust device, a cutter driving device and an organ protection cover, wherein the body is provided with an inner cavity, the top surface and one side surface of which are opened; a dust discharging opening and a worktable for machining graphite materials are arranged at the bottom of the inner cavity; an air inlet is formed in the side wall of the inner cavity; the first automatic door is arranged at the open side surface of the inner cavity, is used for ingression andegression of materials and a cutter, and comprises a first door body and a first door body driving mechanism for driving the first door body to be open and closed; the dust exhaust device is used forcollecting graphite dust and comprises a dust exhaust pipeline connected with the dust discharging opening; the cutter driving device is arranged at the top of the body, is used for clamping the cutter and driving the cuter to machining the graphite materials, and comprises an X-axis driving mechanism, a Y-axis driving mechanism and a Z-axis driving mechanism; and the organ protection cover is paved at the open top of the body. The crown block type graphite machining tool has the effects of improving the protection effect and keeping relatively high machining precision.

The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor.

The invention discloses multifunctional organ protection equipment for radiotherapy. The equipment comprises a bottom plate, wherein a cross beam is arranged below the bottom plate, pressing-type rollers with self-locking devices are arranged at four right angles of the bottom plate, lifting cylinders which can be finely adjusted are arranged at four right angles above the bottom plate, and pistons of the lifting cylinders are fixedly connected with the bottom plate. A supporting plate is fixedly arranged on the outer wall of a cylinder body of the lifting air cylinder, two sides of the long edge of the supporting plate are fixedly connected with a first U-shaped protective material plate, the first U-shaped protective material plate, a second U-shaped protective material plate and a thirdU-shaped protective material plate are movable anti-radiation shielding plates, and other structural materials are carbon fiber materials. Lifting and moving adjustment of the protection bed can be achieved, the application range is wide, adjustment can be performed at any time according to different treatment environments, the protection capacity is high, important organ parts except the radiotherapy part of a patient can be effectively protected on the premise that the radiotherapy position is accurate, scattered rays are prevented from directly irradiating important organs, and the protection effect is good.

The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

An organ protectant solution which is intravenously administered includes a high concentration of cell-impermeant molecules and at least one oncotic agent. The cell-impermeant molecules preferentially load into the interstitial space and the oncotic agent(s) is / are restricted to the vasculature space. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, and maintaining blood circulation and oxygenation of tissues. The organ protectant solution extends the “Golden Hour” for traumatic and / or hemorrhagic shock patients, thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.